{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:26:57Z","timestamp":1787740017527,"version":"build-2784847793"},"reference-count":31,"publisher":"Tsinghua University Press","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.26599\/1671-5411.2023.12.005","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:53:56Z","timestamp":1704340436000},"page":"855-866","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of sacubitril\/valsartan after six months in patients with heart failure with reduced ejection fraction and asymptomatic hypotension"],"prefix":"10.26599","volume":"20","author":[{"given":"An-Hu","family":"WU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Wei","family":"LIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Hao","family":"YANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"HU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"TANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ping","family":"JI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Xia","family":"LU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ejhf.1835","article-title":"Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients","volume":"22","author":"J Cautela","year":"2020","unstructured":"J Cautela. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. 2020, 22: 1357-1365.","journal-title":"Eur J Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/ejhf.1450","article-title":"Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score","volume":"21","author":"C O\u2019Connor","year":"2019","unstructured":"C O\u2019Connor. Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. 2019, 21: 770-778.","journal-title":"Eur J Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.jacc.2019.04.022","article-title":"Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction","volume":"73","author":"C Arundel","year":"2019","unstructured":"C Arundel. Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction. 2019, 73: 3054-3063.","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ejhf.989","article-title":"Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison","volume":"20","author":"P Agostoni","year":"2018","unstructured":"P Agostoni. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. 2018, 20: 700-710.","journal-title":"Eur J Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"O Chioncel","year":"2017","unstructured":"O Chioncel. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. 2017, 19: 1574-1585.","journal-title":"Eur J Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"M B\u00f6hm","year":"2017","unstructured":"M B\u00f6hm. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. 2017, 38: 1132-1143.","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"SJ Greene","year":"2019","unstructured":"SJ Greene. Titration of medical therapy for heart failure with reduced ejection fraction. 2019, 73: 2365-2383.","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ejhf.1054","article-title":"Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study","volume":"20","author":"M Senni","year":"2018","unstructured":"M Senni. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. 2018, 20: 491-500.","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"SJ Greene","year":"2018","unstructured":"SJ Greene. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. 2018, 72: 351-366.","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1161\/CIRCHEARTFAILURE.115.002735","article-title":"Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial","volume":"9","author":"AS Desai","year":"2016","unstructured":"AS Desai. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. 2016, 9: e002735.","journal-title":"Circ Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"JJ McMurray. Angiotensin-neprilysin inhibition versus enalapril in heart failure. 2014, 371: 993-1004.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001073","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"PA Heidenreich. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. 2022, 145: e895-e1032.","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"TA McDonagh. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. 2021, 42: 3599-3726.","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/ehf2.14367","article-title":"Dose titration of sacubitril\/valsartan for heart failure with reduced ejection fraction: a real-world study","volume":"10","author":"C Wang","year":"2023","unstructured":"C Wang. Dose titration of sacubitril\/valsartan for heart failure with reduced ejection fraction: a real-world study. 2023, 10: 1961-1971.","journal-title":"ESC Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3760\/cma.j.cn112148-20221222-01006","article-title":"[Titration strategy of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction and hypotension]","volume":"51","author":"AH Wu","year":"2023","unstructured":"AH Wu. [Titration strategy of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction and hypotension]. 2023, 51: 1098-1103.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2191","author":"","unstructured":"","journal-title":"null"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMx190009","author":"","unstructured":"","journal-title":"null"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jchf.2018.11.011","article-title":"Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry","volume":"7","author":"PA Peri-Okonny","year":"2019","unstructured":"PA Peri-Okonny. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. 2019, 7: 350-358.","journal-title":"JACC Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e006667","DOI":"10.1161\/CIRCHEARTFAILURE.119.006667","article-title":"Treatment differences in chronic heart failure patients with reduced ejection fraction according to blood pressure","volume":"13","author":"JF Veenis","year":"2020","unstructured":"JF Veenis. Treatment differences in chronic heart failure patients with reduced ejection fraction according to blood pressure. 2020, 13: e006667.","journal-title":"Circ Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/clc.23509","article-title":"Novel doses of sacubitril\/valsartan in patients unable to tolerate traditional therapy: effects on N-terminal pro B-type natriuretic peptide levels","volume":"44","author":"AC Pandey","year":"2021","unstructured":"AC Pandey. Novel doses of sacubitril\/valsartan in patients unable to tolerate traditional therapy: effects on N-terminal pro B-type natriuretic peptide levels. 2021, 44: 85-90.","journal-title":"Clin Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"16335","DOI":"10.1038\/s41598-021-95787-w","article-title":"Clinical evidence of initiating a very low dose of sacubitril\/valsartan: a prospective observational analysis","volume":"11","author":"H Kim","year":"2021","unstructured":"H Kim. Clinical evidence of initiating a very low dose of sacubitril\/valsartan: a prospective observational analysis. 2021, 11: 16335.","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/FJC.0000000000000873","article-title":"Beneficial effects of sacubitril\/valsartan at low doses in an Asian real-world heart failure population","volume":"76","author":"J Hu","year":"2020","unstructured":"J Hu. Beneficial effects of sacubitril\/valsartan at low doses in an Asian real-world heart failure population. 2020, 76: 445-451.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1177\/1060028020983522","article-title":"Evaluating sacubitril\/valsartan dose dependence on clinical outcomes in patients with heart failure with reduced ejection fraction","volume":"55","author":"K Kido","year":"2021","unstructured":"K Kido. Evaluating sacubitril\/valsartan dose dependence on clinical outcomes in patients with heart failure with reduced ejection fraction. 2021, 55: 1069-1075.","journal-title":"Ann Pharmacother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00228-021-03210-0","article-title":"Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients","volume":"78","author":"E Corrado","year":"2022","unstructured":"E Corrado. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. 2022, 78: 19-25.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"HY Chang","year":"2019","unstructured":"HY Chang. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. 2019, 74: 372-380.","journal-title":"J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"43","author":"JL Rouleau","year":"2004","unstructured":"JL Rouleau. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. 2004, 43: 1423-1429.","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e004745","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","article-title":"Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril: the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial","volume":"11","author":"O Vardeny","year":"2018","unstructured":"O Vardeny. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril: the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. 2018, 11: e004745.","journal-title":"Circ Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"EJ Velazquez. Angiotensin-neprilysin inhibition in acute decompensated heart failure. 2019, 380: 539-548.","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"R Wachter","year":"2019","unstructured":"R Wachter. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. 2019, 21: 998-1007.","journal-title":"Eur J Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"GMC Rosano","year":"2021","unstructured":"GMC Rosano. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. 2021, 23: 872-881.","journal-title":"Eur J Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ehjcvp\/pvab033","article-title":"Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?","volume":"7","author":"P Ameri","year":"2021","unstructured":"P Ameri. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. 2021, 7: 539-546.","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:53:59Z","timestamp":1704340439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2023.12.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2023.12.005","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}